- Conditions
- Type 2 Diabetes
- Interventions
- placebo, exenatide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 40
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 409
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- insulin glulisine, insulin aspart
- Drug
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Interventions
- FlexTouch®, FlexPen®
- Device
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 65
- States / cities
- Burlingame, California • Concord, California • Encino, California + 59 more
- Conditions
- Type 1 Diabetes
- Interventions
- Artificial Pancreas (AP)
- Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 11 Years to 12 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Primary Insulin-like Growth Factor-1 Deficiency
- Interventions
- mecasermin [rDNA origin] injection
- Biological
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Basking Ridge, New Jersey
- Conditions
- Adrenal Hyperplasia, Congenital
- Interventions
- Hydrocortisone sodium acetate
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Interventions
- Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 24
- States / cities
- Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
- Conditions
- Obesity
- Interventions
- GnRH agonist, Supervised cardiovascular exercise, Placebo
- Drug · Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years to 60 Years · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Healthy Volunteers, Diabetes Mellitus, Type 1
- Interventions
- 18 F-FP-DTBZ, PET Scanning
- Drug · Radiation
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes
- Interventions
- Wosulin N, Novolin N
- Biological
- Lead sponsor
- Wockhardt
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- U-500R
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 1 Diabetes
- Interventions
- Continuous glucose glucose sensor- physician ordered
- Device
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 12 Months to 17 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Tendinopathy, Patellar Ligament, Platelet-Rich Plasma
- Interventions
- Platelet Rich Plasma, Platelet Rich Plasma plus IGF
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- TAK-329, Insulin, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 2 Diabetes, Cardiovascular Risk
- Interventions
- Zenagamtide, Insulin glargine U-100
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 1,778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more
- Conditions
- Obesity, Insulin Resistance
- Interventions
- Anastrazole, Testosterone, Dutasteride, GnRH antagonist
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 24 Years to 51 Years · Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- San Diego, California
- Conditions
- Diabetes Mellitus Type 2 - Insulin-Treated
- Interventions
- Smartphone application and web portal, Standard Insulin Therapy Education
- Device · Behavioral
- Lead sponsor
- Linda Siminerio
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Healthy
- Interventions
- Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- Faster-acting insulin aspart, insulin aspart, insulin degludec
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 32 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Volagidemab
- Biological
- Lead sponsor
- REMD Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- San Deigo, California • Walnut Creek, California
- Conditions
- Obesity, PreDiabetes
- Interventions
- ADI-PEG20, Placebo
- Biological · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 22 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 1 Diabetes
- Interventions
- Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
- Device
- Lead sponsor
- Marc Breton
- Other
- Eligibility
- 24 Months to 71 Months
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Stanford, California • Aurora, Colorado • Charlottesville, Virginia
- Conditions
- Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
- Interventions
- Glucagon for Injection (Fresenius Kabi USA)
- Drug
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Boston, Massachusetts
- Conditions
- Type1 Diabetes
- Interventions
- Glargine
- Biological
- Lead sponsor
- Wockhardt
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chula Vista, California